Vivani Medical (NASDAQ:VANI - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Vivani Medical Stock Down 1.4 %
NASDAQ VANI traded down $0.02 on Friday, reaching $1.09. The company had a trading volume of 23,001 shares, compared to its average volume of 174,585. Vivani Medical has a 52 week low of $1.03 and a 52 week high of $2.22. The stock has a market cap of $64.27 million, a price-to-earnings ratio of -2.41 and a beta of 3.20. The stock's 50 day moving average is $1.15 and its 200-day moving average is $1.22.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Vivani Medical in a research report on Thursday, March 13th.
Check Out Our Latest Research Report on VANI
Vivani Medical Company Profile
(
Get Free Report)
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Featured Stories
Before you consider Vivani Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivani Medical wasn't on the list.
While Vivani Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
